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Future Perspectives 
The use of pseudotyped viruses has historically been limited to a small number of readily 
tractable viruses. However, the flexibility of pseudotyped viruses makes them attractive 
as safe surrogates for enveloped viruses requiring high bio-containment, for use in 
serological screening, assessing vaccine efficacy, targeted gene transduction, virus entry 
inhibition and receptor usage studies. Through the development of more standardized 
protocols, a broader range of reporter genes and backbone viruses, virus pseudotyping 
will become a central and powerful technique in the study and treatment of enveloped 
viruses. 
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Executive Summary 
A pseudotyped virus (PV) is a virus particle with an envelope protein originating from a 
different virus. The ability to dictate which envelope proteins are expressed on the 
surface has made pseudotyping an important tool for basic virological studies such as 
determining the cellular targets of the envelope protein as well as identification of 
potential antiviral compounds and measuring specific antibody responses. In this review, 
we describe the common methodologies employed to generate pseudotyped viruses 
(PVs) with a focus on approaches to improve the efficacy of PV generation. 
What are pseudotyped viruses? 
In 1911, Peyton Rous published the first report of a non-cellular, filterable agent that 
could produce cancer - a sarcoma of chickens [1]. This agent was later named the Rous 
sarcoma virus (RSV) and was used to generate the first virus pseudotypes [2].  
 
Rubin and colleagues [3] discovered that infectious RSV particles were not released from 
sarcoma cells during infection with RSV alone. However, if RSV-transformed sarcoma 
cells were co-infected with a helper avian leukosis virus, Rous-associated virus (RAV), 
then infectious RSV and RAV progeny were released (as RSV and RAV are antigenically-
unrelated avian C-type retroviruses they could be distinguished). Importantly, it was 
also shown that the RSV particles produced possessed the RSV genome but the RAV 
outer ‘coat’, as determined by serology and cell tropism [2, 3]. They called these hybrid 
particles ‘pseudotypes’.  
 
A serendipitous property of retroviruses such as RSV is their natural ability to 
incorporate other cellular proteins, including the envelope proteins of other viruses [4-
6]. The discovery that human immunodeficiency virus 1 (referred to as HIV in this 
review) effectively incorporates the envelope proteins from human T-lymphotrophic virus 
1 (HTLV-1) [4] provided evidence that this virus is a tractable platform for making 
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recombinant PVs. Murine leukemia virus (MLV, also referred to as MuLV or Moloney 
murine leukemia virus, MoMLV) was independently discovered to assemble infectious 
particles with HTLV-1 envelope proteins [7].  
 
Nomenclature has developed alongside molecular knowledge. The protein nucleocapsid 
encasing the ribonucleic acid (RNA) genome is now known as the ‘core’ and the outer 
membrane of these virus particles, derived from the host cell membrane during viral 
egress by ‘budding’, as an ‘envelope’. Thus proteins embedded in the membrane become 
incorporated in the viral envelope and define particle antigenicity and cell tropism.  Here, 
the term ‘pseudotyped virus’ (PV) is defined as an enveloped virus particle comprising a 
virus capsid/matrix/core surrounded by a cell-derived membrane bearing the foreign 
virus envelope protein(s) (VEP). The genetic material packaged by a PV does not encode 
a VEP. Therefore, a PV is capable only of entering and transducing a target cell, initiating 
nucleic acid replication without producing infectious particles. Depending upon end-user 
application, PVs have been variously referred to as pseudotypes, pseudo-viruses, 
pseudo-particles, virus pseudotypes, lenti- or retrovirus vectors, trans-complemented 
viruses, gene transfer vectors, reporter virus particles and virus-like particles. It is 
important to note that many of these terms have also been used to describe particles or 
techniques that do not fit the above definition. The term ‘virus envelope protein’ is used 
rather than ‘virus glycoproteins’ to include non-glycosylated viral surface proteins such 
as the mature form of the flavivirus M protein and exclude glycosylated non-structural 
proteins. Furthermore, the distinction between VEP and ‘virus surface protein’ 
distinguishes PVs from techniques involving non-enveloped viruses (e.g. adeno-
associated virus vectors). 
 
A functional PV can be generated by transfection of a ‘producer’ cell with three plasmids 
(Figure 1).  The PV ‘backbone’ is a virus that provides both the core and the recombinant 
genome packaged by PVs. This combination is essential because genome packaging is 
mediated by specific interactions between sequences in the genome and the 
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core/matrix/capsid. The most commonly used PV backbones are HIV or MLV retroviruses 
for which the core expression plasmid encodes the gag and pol genes with no packaging 
signal. The recombinant genome is typically a reporter gene such as luciferase flanked 
by retroviral long terminal repeats (LTRs) and a packaging signal (ψ). The third plasmid 
expresses the open reading frame of the VEP of the virus of interest with appropriate 
signal peptide.  
Applications of pseudotyped viruses (PVs) 
The flexibility of PVs means that they are suitable for a wide range of applications. A key 
feature of PVs is that they cannot replicate apart from the reporter gene maintained as 
the genome; they are therefore widely used at ACDP/BSL 1 or 2 (regardless of the origin 
of the VEP) and have been particularly valuable in the study of highly pathogenic 
viruses. 
 
PVs for research and therapeutic agent screening 
PVs offer the ability to rapidly generate key data in the characterization of virus–host 
interactions. The use of PVs has been of crucial significance in the rapid pace of research 
into the Middle Eastern Respiratory syndrome (MERS) outbreak [8-11]. During the 
recent Ebola outbreak, PVs were successfully used in high-throughput screening studies 
that helped in the identification of potential antivirals and filovirus entry inhibitors [12-
14] as well as in the study of the viral life cycle and virus receptor interaction [15].  
 
PVs have been used extensively to investigate the entry cascade of hepatitis C virus 
(HCV) for which, until recently, a robust in vitro cell-culture system did not exist for 
primary virus isolates. The two glycoproteins of HCV, E1 and E2, have been successfully 
expressed and incorporated into PVs, initially as modified glycoproteins into VSV 
backbones [16], then later as unmodified constructs using VSV [17], MLV [6] and HIV 
[18] backbones. The entry pathway of genetically diverse HCV strains was dissected 
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using these experimental systems, revealing a requirement for an array of receptors 
[19-23]. Both E1 and E2 are required for assembly of infectious PVs with E2 acting as a 
chaperone for E1 incorporation, interacting with both E1 and the retroviral core [24]. 
Using PVs to investigate the effects of specific point mutations on HCV entry also 
revealed key amino acids involved in receptor interactions [25-27]. However, 
comparison with authentic HCV viruses revealed that PVs are less tolerant to alteration 
in vitro.  
PVs for measuring antibodies 
PVs have been used as surrogates of wild-type viruses in sensitive, high throughput 
neutralization assays (PVNAs), also referred to as pseudotyped particle- (pp-) or 
pseudotyped virus-based microneutralization assays (pv-MN). For most PVNAs, serial 
dilutions of sera are incubated with a pre-determined amount of a PV (quantified by the 
measurement of reporter gene expression) for one hour at 37°C. A fixed amount of 
virus-susceptible target cells is then added and reporter gene expression measured after 
an appropriate incubation period (e.g. 48 hours) [28]. The titer of antibody is typically 
expressed as the highest dilution of the sample that reduces reporter gene expression by 
either 50% (IC50) or 90% (IC90) compared to controls [29]. The PVNA is typically 
sample-sparing. The option to incorporate a number of different reporter genes means 
that PVs can be adapted to a multiplex serum screening format [30, 31].  
 
Comparative serology studies for highly pathogenic avian influenza (HPAI) of the H5 
subtype have shown that results from more traditional serological assays including 
hemagglutination inhibition, micro-neutralization and single radial hemolysis correlate 
well with those obtained by PVNA [32]. It is thought that a lower density of 
hemagglutinin (HA) on the surface of influenza PVs compared to wild-type virus means 
that a sub-set of antibodies are better able to access cross-reactive epitopes on the stalk 
of the VEP. The PVNA can therefore be used to measure antibodies generated by 
prototype ‘universal vaccines’ composed of HA stem fragments. These antibodies cannot 
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be measured by the classical hemagglutination inhibition test as this relies on measuring 
blocking of antibodies against the receptor-binding site on the globular head of the HA, 
which is missing [33, 34].  
 
PVs have also been widely used to investigate neutralization of HCV entry. The PVNA was 
first established to test the neutralizing potency of sera [35-37] and monoclonal 
antibodies [38-42] against diverse strains of HCV. This revealed the existence of 
broadly-neutralizing antibodies generated during natural infection [43, 44] and following 
immunization with vaccines [45, 46]. Studies using PVs demonstrated that serum 
contains factors other than antibodies that have the potential to neutralize HCV entry 
[47-49], while the apolipoprotein components  of serum can enhance HCV infectivity and 
protect against antibody-mediated neutralization [50, 51]. Direct comparison of HCV PVs 
and wild-type HCV viruses revealed that PVs are more resistant to antibody-mediated 
neutralisation [41], suggesting that PVNA might over-estimate the amounts of antibody 
required for clinical administration.  
 
Retroviral PVs bearing the HIV-1 glycoproteins have also been used for high throughput 
PVNA and assessment of vaccine-induced immunity. Comparison of an array of different 
assays in multiple laboratories found that PVs were generally more sensitive to 
neutralization than replicating viruses [52, 53], confirming previous findings [54]. As 
such, PVs might not accurately determine the neutralization potency of inhibitors against 
a single virus strain, but provide a powerful and rapid method for comparing the 
neutralization sensitivity of many different strains.  
PVs as vaccines 
The production of neutralizing antibodies is a hallmark of successful vaccination resulting 
in protection against virus infections (reviewed in [55]). As VEPs are the key targets of 
neutralizing antibodies, PVs capable of expressing different proteins might be a very 
useful platform for vaccine design. Indeed, immunization with VSV-based PVs has been 
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shown to protect mice against challenge with influenza [56]. However, disadvantages 
include the potential risk of genomic integration (see below) and lack of sustained 
antigen production, and greater efforts have been made to develop virus-like particle 
(VLP)-based vaccines (reviewed in [57]).  
PVs for gene transfer 
The comparative ease with which VEPs can be swapped has been exploited to produce 
retrovirus delivery vectors for gene transfer where the integration of packaged transgene 
into the target cell genome enables longer-term gene expression compared with the 
episomal vectors, typified by many DNA viruses. The first gene therapy vectors were 
based on retroviruses with their gag, pol and env regions removed and replaced with a 
therapeutic gene and sometimes a selective marker. During vector production, the gag, 
pol and env protein products were supplied in trans by suitable stable packaging cell 
lines. Although the first gene therapy trial employed a retrovirus vector with its cognate 
envelope protein [58], soon after, heterologous retrovirus envelopes were used, 
primarily to enhance target cell transduction and thus therapeutic gene expression [59].  
One issue with the original C-type retrovirus vectors (e.g. MLV) was that they were only 
able to transduce dividing cells. To address this issue, researchers turned to the 
lentiviruses (e.g. HIV), which do not require replicating cells for efficient transduction. 
 
Another issue has been that of insertional mutagenesis as a result of genomic integration 
of the transfer gene causing activation of oncogenes [60]. Though a rare occurrence, it 
did manifest itself by producing leukemia in five patients several years after gene 
therapy for severe combined immunodeficiency [61]. It is believed that the viral control 
elements situated in the retrovirus LTRs activate host genes. Consequently, self-
inactivating vectors have been designed which eliminate these elements [62]. 
In order to alter the natural cell tropism of transfer vectors, heterologous envelope 
glycoproteins have been employed with varying degrees of success [63]. VSV-G was 
used for pseudotyping retrovirus vectors [64] to broaden the range of target cells, 
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tissues and species, and has been widely adopted since. Conversely, pseudotyping 
provides the means to retarget viral vectors for transduction of particular targets, such 
as lung, central nervous system, kidney, liver and hematopoietic cells [63]. 
Considerations for developing novel pseudotyped viruses 
Many different viruses have been pseudotyped. However there is no single standardized 
experimental approach. There are many factors that need to be considered when 
generating a novel virus pseudotype, taking into account numerous aspects of the virus 
biology, the intended application and how tractable the virus is to forming PVs. These 
are expanded upon in the following sections and summarized in Figure 2. 
The "plug and play" pseudotype construction model is exemplified by influenza PVs 
assembled using retroviral cores. With a toolkit of 6 plasmids and a streamlined 
optimization grid for transfection, most strains of influenza are currently amenable to 
pseudotyping onto retroviral cores [65-67]. Essentially these assembly processes fall 
broadly into three protocols with the one chosen being dependent on the HA to be 
pseudotyped and also the downstream application. The simplest system is employed for 
generating PVs from highly pathogenic avian influenza viruses of the H5 and H7 
subtypes which possess multi-basic HA cleavage sites. These are ideal when only HA-
mediated cell entry is required as there will be no neuraminidase (NA) on the released 
PVs [68, 69]. Inclusion of a plasmid encoding NA generates particles that more closely 
mimic their cognate wild-type virus, which is useful for surveillance and vaccine 
immunogenicity studies (whole virus vaccines). In order to effectively pseudotype HAs 
that possess a monobasic HA cleavage site (e.g. from seasonal human influenza 
viruses), a protease must be supplied (as described below).  
 
Viral backbones for pseudotyping  
As previously mentioned, HIV or MLV retroviruses are the most commonly used 
backbones for PV production. The HIV backbone for PVs has undergone several iterations 
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to improve safety including the deletion of accessory proteins, promoter sequences and 
the provision of the HIV rev gene on a separate fourth plasmid (reviewed in [70]). 
Systems are also available whereby the reporter gene is encoded on the gag-pol plasmid 
reducing it to a two plasmid transfection system. When establishing a novel virus PV 
system it may be relevant to consider which generation of HIV backbone to use as it has 
been reported that nef co-expression enhanced PV assembly of VEPs from retroviruses, 
but not non-retroviruses, on the HIV backbone [71]. Two and three plasmid systems, 
comparable to the lentivirus system, exist for MLV. MLV is non-pathogenic in humans 
and has fewer accessory proteins compared to HIV. It was the preferred PV backbone 
prior to development of the second and third generation HIV systems but the two 
retrovirus backbones are now comparable in terms of safety and ease of use. 
 
Not all VEPs are incorporated efficiently into HIV or MLV backbones [72]; the choice of 
backbone for pseudotyping a novel virus may be informed by reports of successful 
systems published for related viruses.  The vesicular stomatitis virus (VSV) system, 
which was originally applied to the study of Ebola virus (EBOV) envelope proteins [73], 
provides an alternative. VSV is a single-stranded negative sense RNA virus encoding 5 
genes that are transcribed on separate mRNAs, enabling deletion or substitution of any 
given gene for a heterologous gene. PVs can be generated by combining a recombinant 
VSV genome, in which the VSV-G gene has been deleted (rVSV-ΔG*) and is replaced 
with a reporter gene, with an expression plasmid encoding the desired VEP(s).  
 
Establishment of the rVSV-ΔG* system is complex (Figure 3). In order to initiate 
replication of the rVSV-ΔG* genome, cells must be transfected with the pVSV-ΔG* 
genome plasmid and plasmids expressing the VSV nucleoprotein (N), phosphoprotein (P) 
and polymerase protein (L). Furthermore, initial transcription of the VSV-ΔG* genome 
from the plasmid is controlled by the T7 RNA polymerase promoter (T7 pol). T7 pol is 
commonly provided by one of two methods: infection of the producer cells with a 
recombinant virus expressing T7 pol (modified vaccinia virus Ankara (MVA)-T7 or 
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fowlpox virus (FPV)-T7) or by using a clone of the BHK-21 cell line stably expressing T7 
pol from a plasmid [74]. T7 helper viruses are preferred because they achieve higher 
levels of T7 pol activity compared to stable cell lines. The addition of a VSV-G expression 
plasmid results in the production of particles encapsidating the VSV-ΔG* genome and 
coated with VSV-G, or VSV-pseudotyped rVSV. Infection of target cells (lacking the T7 
pol and the VSV accessory protein expression plasmids) with these PVs leads to efficient 
replication of the VSV-ΔG* genome and production of non-infectious ΔEnv-rVSV. 
Therefore transfection of cells with a heterologous VEP expression plasmid and 
subsequent infection with VSV-pseudotyped rVSV particles leads to the production of 
heterologous VEP-pseudotyped rVSV. However, due to the high efficiency of VSV-G 
pseudotyping, it is important to assess PV neutralization with antibodies against the 
heterologous virus envelope and VSV-G to confirm the composition of the PVs. A 
comprehensive method for the production of VSV-based PVs is given in [75].  
Provision of proteases 
Many viruses make use of host cell proteases for the production or release of mature 
virus particles. Furthermore, protease usage can be a critical determinant of viral 
tropism [76]. For seasonal human influenza viruses, the requirement for protease-
mediated cleavage of the hemagglutinin in order for it to become fusion competent is a 
well-documented trait [65, 77-79]. However, protease activation is also a well-studied 
component in the Paramyxoviridae (a family of negative sense single-strand RNA 
viruses), where the F protein precursor must be cleaved in order to facilitate maturation 
of the fusion protein [80], and in the Coronaviridae (a family of positive sense, single-
strand RNA viruses) where proteases can be involved in both cleavage of the spike 
protein and facilitating release from the host cell [81-83].  Therefore, it may be 
necessary to supplement PV generation protocols with specific proteases. In many 
studies it has become common practice to co-transfect a protease-encoding plasmid 
alongside the other plasmids required for PV production [65, 77, 79, 84]. For influenza, 
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the most commonly used proteases when supplied as a plasmid are HAT and TMPRSS2 
[77].   
 
It is also possible to induce protease-mediated activation through the addition of purified 
protease to the culture medium or purified PV preparation. The addition of exogenous 
tosyl phenylalanyl chloromethyl ketone (TPCK) trypsin has been demonstrated to 
facilitate activation of SARS-CoV [85, 86] MERS-CoV [10, 87] and human coronavirus 
229E [88]. Exogenous TPCK trypsin is also used for influenza, but an additional step is 
required in order to deactivate the protease, using commercially available protease 
inhibitors, prior to inoculation of the PVs onto target cells [65, 77]. 
 
Signal peptides and transmembrane domains 
Appropriate signal peptides (SPs) and transmembrane domains (TMDs) are a key 
component of successful PV production as they contribute to sub-cellular targeting and 
membrane retention of the VEP. It is necessary to target VEPs to the endoplasmic 
reticulum to facilitate trafficking to sites of assembly. The exact site of retrovirus 
budding is yet to be completely defined. The cytoplasmic tails of VEPs have also been 
identified as important factors [89-91]. Gibbon ape leukemia virus (GaLV) required the 
cytoplasmic domains of MLV glycoproteins to form PVs on an HIV-1 backbone [92]. 
 
VEP alteration 
The diverse structure of VEPs, a characteristic used to divide them into three major 
classes (I–III), can be the cause of their inefficient incorporation into PVs and 
consequently poor viral titers. Issues such as localization to the Golgi complex may be 
overcome by splicing together different sections of heterologous VEPs, to generate 
chimeric proteins. The structure of a VEP can be crudely broken down into the ecto-, 
transmembrane and cytoplasmic domains. Ectodomains play the major role in cell 
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binding and antigenicity so any alterations could affect serological and tropism properties 
of the VEP so this domain should usually be maintained. However, several studies have 
shown that switching of the cytoplasmic domains is one mechanism by which PV titers 
can be improved [16, 93, 94]. Carpentier et al. conducted a detailed series of 
experiments to determine if titers of lentiviral PV bearing the rabies virus envelope 
protein (RABV-G) could be improved by engineering chimeric VEPs [94]. By swapping in 
the corresponding domains from VSV-G they were able to generate a series of chimeric 
VEPs and determine efficiency of VEP incorporation into PVs and infectivity. The only 
chimera that led to an increase in PV titer comprised the RABV-G ecto- and 
transmembrane domains with the VSV-G cytoplasmic domain. This work has been 
expanded by Bentley et al. who showed that RABV-G which previously gave no or very 
low/unusable PV titers could successfully be pseudotyped by swapping the cytoplasmic 
domain for that of VSV-G [95]. However, it is important to note that there is some 
variation within the literature about the exact sequence for the VSV cytoplasmic domain 
[16, 96, 97]. 
 
The reason chimeric VEPs result in better incorporation of VEP and higher PV titer is 
unclear. It could be due to a stronger interaction with the backbone matrix/capsid 
protein if the cytoplasmic domain being introduced is shorter as this may reduce steric 
hindrance. Alternatively, the chimeric VEPs may be trafficked more efficiently to the sites 
from which the backbone virus naturally buds. 
 
Other modifications to VEPs can boost titers. Measles virus has two envelope proteins, F 
and H, and it has been shown that if the full-length wild-type VEPs are used then only 
very small quantities of infectious PV are produced [98]. However, if both VEPs are 
truncated, H24 and F30, levels of incorporation into PV and the PV titer are both 
markedly higher. 
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Optimizing PV titers 
The VSV glycoprotein (VSV-G) produces high titer PVs and is therefore commonly used 
as a positive control in developing novel PVs. Hepatitis B virus represents the other 
extreme where existing systems result in very low infectious PV titers [99]. 
Quantification of PVs obtained 
PV titer is most commonly determined by measuring reporter gene expression in 
susceptible target cell lines. However, if little or no expression is seen, it may be 
necessary to conduct further tests. For retrovirus-based PVs this appears to 
underestimate the number of cells that have undergone genome integration, due to 
variability of marker expression; PCR has been employed to determine this more 
precisely [100, 101]. Titration of viral genomic RNA from producer line supernatants 
conversely overestimates the number of infectious particles due to the presence of 
defective interfering particles. Titration of HIV-based PV preparations can also be 
performed by Gag (p24) protein ELISA [102] with infectivity defined as number of 
infectious units per unit of p24. Lastly, titration of several retroviral vectors based on 
reverse transcriptase activity via qPCR has recently been reported [103]. 
 
Virus particle analysis has historically been conducted via electron microscopy. However, 
new technologies (e.g. nanoparticle tracking analysis) have enabled rapid quantification 
of virus particles and determination of particle size [104]. The continued development of 
such systems may provide vital information on the efficacy of PV production, both in 
terms of quantity and quality. 
 
If low titers of PV production are demonstrated, there are several measures that can be 
taken to boost these to more usable levels as described below. On the other hand, if no 
detectable titers are observed, it may be necessary to change the approach (for example 
using a different backbone or generating a chimeric VEP).  
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Concentration of PVs  
Ultracentrifugation combined with a sucrose cushion or gradient can be used to 
concentrate PVs [18, 105]. Concentration of PVs can also be performed using 
polyethylene glycol (PEG)-precipitation. PEG precipitation has advantages over 
ultracentrifugation, which requires expensive equipment, and low speed centrifugation, 
which can be time consuming. Optimization of incubation time and molecular weight and 
concentration of PEG used will all be required, however numerous commercial kits are 
available with specific protocols. An optimized method for MLV uses 8.5% (w/v) PEG 
6000 for 90 minutes at 4°C followed by collection of the precipitate by centrifugation at 
7,000 x g for 10 minutes [106, 107]. 
 
Influence of plasmid and codon optimization 
Codon optimization is used to increase the expression of a protein in organisms by 
increasing translational efficiency. Most amino acids are encoded by more than one 
codon with each codon recognized by a specific tRNA. Organisms have developed 
individual preferences for particular codons for a given amino acid (known as ‘codon 
usage bias’). As the efficient generation of PVs requires good levels of VEP expression in 
the producer cells, codon optimization relevant for the given producer cell line may 
improve viral titers [108-111].  
 
The plasmids used to encode the VEP(s) can also greatly influence expression levels and 
therefore PV titer [112, 113]. In order to maximize the level of VEP expression, plasmids 
with strong promotor elements are used such as pcDNA, pCAGGS or phCMV. Expression 
in these plasmids is driven by either the human cytomegalovirus major immediate early 
or beta-actin promotor, two of the strongest promotors that have been identified. As 
pcDNA- and phCMV-based plasmids are commercially available they negate downstream 
intellectual property conflicts. 
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The methods of producing PVs on both the VSV and retroviral backbones involve 
transfection of producer cells with multiple plasmids. Establishing successful transfection 
of plasmids in appropriate ratios appears to be important for successful generation of 
infectious PVs. Experiments with HIV-based PVs demonstrated that differences in 
infectivity occur with different amounts of the VEP plasmid [114]. This also occurs for 
MLV-based PVs, with the amount of VEP plasmid being finely tuned to the species of 
virus being pseudotyped [115].  Interestingly, maximal expression of VEP did not always 
correlate with maximal infectivity, suggesting that optimization of the ratio of expression 
of viral capsid genes to VEP might be important to generating infectious particles. 
Use of PV packaging cell lines 
Cell lines stably expressing one or more components of the PV system have been 
developed to standardize and simplify PV production and reduce transfection costs.  
 
Transfecting cells with a plasmid encoding a lentivirus or retrovirus backbone with 
functional LTRs but with a deletion for the packaging signal (ψ) [116] results in ‘PV 
packaging cells’ that continually express high levels of the capsid and enzymes required 
for retrovirus-based PV production. Subsequent transfection of these cells with plasmids 
encoding a VEP gene and a reporter gene, with ψ signal and LTRs, results in the 
production of functional PVs. Specific packaging cell lines have also been generated by 
maintaining episomal replication of a plasmid encoding the backbone gag-pol genes 
using selection markers [117]. Packaging cell lines have been produced for a range of PV 
backbones, including HIV, MLV and FeLV, and are available commercially. More recently, 
a lentivirus packaging cell line was developed specifically to meet clinical approval 
standards for the generation of PVs for gene therapy by inserting the HIV gag-pol genes 
into the genome of 293FT cells using Cre recombinase mediated cassette exchange 
(RMCE) [118].  
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It is well known that VSV-pseudotyped retrovirus PVs result in high levels of reporter 
gene expression in producer cells due to transduction of the reporter gene at multiple 
sites in the genome [119]. Therefore, transduction of producer cells with VSV-
pseudotyped retrovirus PVs packaging the gene encoding the VEP(s) for a novel virus will 
generate a cell line with potentially high levels of VEP expression. This may be 
appropriate for novel PV candidate viruses with poor envelope protein expression levels. 
 
Improved interaction of PVs with target cells 
During development of entry models for HCV, large differences in PV transduction of 
target cells were observed  [19, 114, 120], in particular PVs representing HCV genotype 
3 were associated with lower infectivity ([19]; unpublished results). As a result, some 
methodologies have used polybrene, or ‘spinoculation’ to increase observed infectivity 
[114, 121].  
 
As a result of their amino acid composition, VEPs are negatively charged. This can limit 
the initial and sometimes non-specific interaction between the VEP and molecules on the 
target cell surface [122]. Addition of polybrene (hexadimethrine bromide), a cationic 
polymer, to the cell culture media (typically at a final concentration of 8μg/ml) is thought 
to reduce the charge repulsion between the negatively charged VEPs and receptors such 
as sialic acid or increasing virus aggregation [123]. Spinoculation involves centrifuging 
VPs onto the target cell surface. Both methods have the effect of increasing observed 
signal, but increase the complexity of the downstream applications. 
Conclusions 
The generation of PVs has facilitated progress in research involving highly pathogenic 
viruses and has been beneficial to research involving viruses for which in vitro culture 
methods have not been available. Despite the many success stories, pseudotyping of 
members of some virus families (e.g. the Flaviviridae) has yet to become a routine 
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procedure. Even within virus families for which PVs have been successfully generated, 
not all subtypes of strains can be predictably pseudotyped by the same methods. In 
summary, there are numerous factors to be taken into consideration when generating 
PVs. As the field develops, the range of choice of viral backbones and reporter genes is 
expanding and progress is being made towards the standardization of protocols for 
consistency, which is essential for some of the main applications of PVs. Novel viruses 
may pose technical barriers to pseudotyping, but the resultant PVs will provide a 
powerful tool to dissect aspects of virus binding and entry as well as in the development 
of antivirals and vaccines. 
  
  
18 
 
References 
1. Rous P. A Sarcoma of the Fowl Transmissible by an Agent Separable from the 
Tumor Cells. J Exp Med 13(4), 397-411 (1911). 
2. Rubin H. Genetic Control of Cellular Susceptibility to Pseudotypes of Rous 
Sarcoma Virus. Virology 26 270-276 (1965). 
3. Hanafusa H, Hanafusa T, Rubin H. The defectiveness of Rous sarcoma virus. Proc 
Natl Acad Sci U S A 49 572-580 (1963). 
4. Landau NR, Page KA, Littman DR. Pseudotyping with human T-cell leukemia virus 
type I broadens the human immunodeficiency virus host range. J Virol 65(1), 162-169 
(1991). 
5. Page KA, Landau NR, Littman DR. Construction and use of a human 
immunodeficiency virus vector for analysis of virus infectivity. J Virol 64(11), 5270-5276 
(1990). 
6. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles 
containing functional E1-E2 envelope protein complexes. J Exp Med 197(5), 633-642 
(2003). 
* This paper was the first description of a tractable experimental system for 
interrogating the hepatitis C virus entry pathway and the effect of genetic diversity on 
entry fitness. It also facilitated assessment of the potency of HCV-neutralising 
antibodies. 
7. Vile RG, Schulz TF, Danos OF, Collins MK, Weiss RA. A murine cell line producing 
HTLV-I pseudotype virions carrying a selectable marker gene. Virology 180(1), 420-424 
(1991). 
8. Corti D, Zhao J, Pedotti M et al. Prophylactic and postexposure efficacy of a 
potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 
112(33), 10473-10478 (2015). 
9. Perera RA, Wang P, Gomaa MR et al. Seroepidemiology for MERS coronavirus 
using microneutralisation and pseudoparticle virus neutralisation assays reveal a high 
  
19 
 
prevalence of antibody in dromedary camels in Egypt, June 2013. Euro surveillance : 
bulletin Europeen sur les maladies transmissibles = European communicable disease 
bulletin 18(36), pii=20574 (2013). 
10. Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human 
Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia 
formation. PloS one 8(10), e76469 (2013). 
11. Zhao G, Du L, Ma C et al. A safe and convenient pseudovirus-based inhibition 
assay to detect neutralizing antibodies and screen for viral entry inhibitors against the 
novel human coronavirus MERS-CoV. Virology journal 10 266 (2013). 
12. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against 
Ebola and other emerging viral diseases using existing medicines that block virus entry 
[v1; ref status: awaiting peer review].  4, (2015). 
13. Cote M, Misasi J, Ren T et al. Small molecule inhibitors reveal Niemann-Pick C1 is 
essential for Ebola virus infection. Nature 477(7364), 344-348 (2011). 
14. Basu A, Mills DM, Mitchell D et al. Novel Small Molecule Entry Inhibitors of Ebola 
Virus. J Infect Dis doi:10.1093/infdis/jiv223 (2015). 
15. Kuroda M, Fujikura D, Nanbo A et al. Interaction between TIM-1 and NPC1 Is 
Important for Cellular Entry of Ebola Virus. J Virol 89(12), 6481-6493 (2015). 
16. Lagging LM, Meyer K, Owens RJ, Ray R. Functional role of hepatitis C virus 
chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol 72(5), 3539-3546 
(1998). 
17. Tani H, Komoda Y, Matsuo E et al. Replication-competent recombinant vesicular 
stomatitis virus encoding hepatitis C virus envelope proteins. J Virol 81(16), 8601-8612 
(2007). 
18. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-
dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 
100(12), 7271-7276 (2003). 
  
20 
 
19. Lavillette D, Tarr AW, Voisset C et al. Characterization of host-range and cell 
entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 
41(2), 265-274 (2005). 
20. Meertens L, Bertaux C, Cukierman L et al. The tight junction proteins claudin-1, -
6, and -9 are entry cofactors for hepatitis C virus. J Virol 82(7), 3555-3560 (2008). 
21. Zheng A, Yuan F, Li Y et al. Claudin-6 and claudin-9 function as additional 
coreceptors for hepatitis C virus. J Virol 81(22), 12465-12471 (2007). 
22. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins 
claudin-1 and occludin control hepatitis C virus entry and are downregulated during 
infection to prevent superinfection. J Virol 83(4), 2011-2014 (2009). 
23. Bartosch B, Vitelli A, Granier C et al. Cell entry of hepatitis C virus requires a set 
of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J 
Biol Chem 278(43), 41624-41630 (2003). 
24. Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B. Assembly of 
functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs 
intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen 
Virol 86(Pt 12), 3189-3199 (2005). 
25. Goffard A, Callens N, Bartosch B et al. Role of N-linked glycans in the functions of 
hepatitis C virus envelope glycoproteins. J Virol 79(13), 8400-8409 (2005). 
26. Owsianka AM, Timms JM, Tarr AW et al. Identification of conserved residues in 
the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J 
Virol 80(17), 8695-8704 (2006). 
27. Rothwangl KB, Manicassamy B, Uprichard SL, Rong L. Dissecting the role of 
putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding 
region 1 is not involved in CD81 binding. Virology journal 5 46 (2008). 
28. Mather S, Scott S, Temperton N, Wright E, King B, Daly J. Current progress with 
serological assays for exotic emerging/re-emerging viruses. Future Virology 8(8), 745-
755 (2013). 
  
21 
 
29. Molesti E, Milani A, Terregino C, Cattoli G, Temperton NJ. Comparative Serological 
Assays for the Study of H5 and H7 Avian Influenza Viruses. Influenza Research and 
Treatment 2013 9 (2013). 
30. Molesti E, Wright E, Terregino C, Rahman R, Cattoli G, Temperton NJ. Multiplex 
evaluation of influenza neutralizing antibodies with potential applicability to in-field 
serological studies. J Immunol Res 2014 457932 (2014). 
31. Wright E, Hayman DT, Vaughan A et al. Virus neutralising activity of African fruit 
bat (Eidolon helvum) sera against emerging lyssaviruses. Virology 408(2), 183-189 
(2010). 
32. Alberini I, Del Tordello E, Fasolo A et al. Pseudoparticle neutralization is a reliable 
assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 
27(43), 5998-6003 (2009). 
33. Mallajosyula VV, Citron M, Ferrara F et al. Influenza hemagglutinin stem-fragment 
immunogen elicits broadly neutralizing antibodies and confers heterologous protection. 
Proc Natl Acad Sci U S A 111(25), E2514-2523 (2014). 
34. Corti D, Voss J, Gamblin SJ et al. A Neutralizing Antibody Selected from Plasma 
Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science 
333(6044), 850-856 (2011). 
35. Bartosch B, Bukh J, Meunier JC et al. In vitro assay for neutralizing antibody to 
hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad 
Sci U S A 100(24), 14199-14204 (2003). 
36. Yu MY, Bartosch B, Zhang P et al. Neutralizing antibodies to hepatitis C virus 
(HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U 
S A 101(20), 7705-7710 (2004). 
37. Meunier JC, Engle RE, Faulk K et al. Evidence for cross-genotype neutralization of 
hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. 
Proc Natl Acad Sci U S A 102(12), 4560-4565 (2005). 
  
22 
 
38. Owsianka A, Tarr AW, Juttla VS et al. Monoclonal antibody AP33 defines a broadly 
neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79(17), 
11095-11104 (2005). 
39. Johansson DX, Voisset C, Tarr AW et al. Human combinatorial libraries yield rare 
antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104(41), 
16269-16274 (2007). 
40. Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against 
hepatitis C virus quasispecies challenge. Nat Med 14(1), 25-27 (2008). 
41. Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal 
antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89(Pt 3), 653-659 (2008). 
42. Perotti M, Mancini N, Diotti RA et al. Identification of a broadly cross-reacting and 
neutralizing human monoclonal antibody directed against the hepatitis C virus E2 
protein. J Virol 82(2), 1047-1052 (2008). 
43. Netski DM, Mosbruger T, Depla E et al. Humoral immune response in acute 
hepatitis C virus infection. Clin Infect Dis 41(5), 667-675 (2005). 
44. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing 
antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad 
Sci U S A 104(14), 6025-6030 (2007). 
45. Wong JA, Bhat R, Hockman D et al. Recombinant hepatitis C virus envelope 
glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope 
glycoproteins associated with broad cross-neutralization. J Virol 88(24), 14278-14288 
(2014). 
46. Colombatto P, Brunetto MR, Maina AM et al. HCV E1E2-MF59 vaccine in chronic 
hepatitis C patients treated with PEG-IFNalpha2a and Ribavirin: a randomized controlled 
trial. J Viral Hepat 21(7), 458-465 (2014). 
47. Brown KS, Keogh MJ, Owsianka AM et al. Specific interaction of hepatitis C virus 
glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 1(7), 664-674 
(2010). 
  
23 
 
48. Hamed MR, Brown RJ, Zothner C et al. Recombinant human L-ficolin directly 
neutralizes hepatitis C virus entry. J Innate Immun 6(5), 676-684 (2014). 
49. Zhao Y, Ren Y, Zhang X et al. Ficolin-2 inhibits hepatitis C virus infection, 
whereas apolipoprotein E3 mediates viral immune escape. J Immunol 193(2), 783-796 
(2014). 
50. Lavillette D, Morice Y, Germanidis G et al. Human serum facilitates hepatitis C 
virus infection, and neutralizing responses inversely correlate with viral replication 
kinetics at the acute phase of hepatitis C virus infection. J Virol 79(10), 6023-6034 
(2005). 
51. Bankwitz D, Vieyres G, Hueging K et al. Role of hypervariable region 1 for the 
interplay of hepatitis C virus with entry factors and lipoproteins. J Virol 88(21), 12644-
12655 (2014). 
52. Heyndrickx L, Heath A, Sheik-Khalil E et al. International network for comparison 
of HIV neutralization assays: the NeutNet report II. PloS one 7(5), e36438 (2012). 
53. Fenyo EM, Heath A, Dispinseri S et al. International network for comparison of 
HIV neutralization assays: the NeutNet report. PloS one 4(2), e4505 (2009). 
54. Louder MK, Sambor A, Chertova E et al. HIV-1 envelope pseudotyped viral 
vectors and infectious molecular clones expressing the same envelope glycoprotein have 
a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is 
associated with decreased neutralization sensitivity. Virology 339(2), 226-238 (2005). 
55. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 
17(7), 1055-1065 (2010). 
56. Roberts A, Kretzschmar E, Perkins AS et al. Vaccination with a recombinant 
vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete 
protection from influenza virus challenge. J Virol 72(6), 4704-4711 (1998). 
57. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient 
vaccine platform: diversity of targets and production systems and advances in clinical 
development. Vaccine 31(1), 58-83 (2012). 
  
24 
 
58. Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for 
ADA- SCID: initial trial results after 4 years. Science 270(5235), 475-480 (1995). 
59. Onodera M, Nelson DM, Yachie A et al. Development of improved adenosine 
deaminase retroviral vectors. J Virol 72(3), 1769-1774 (1998). 
60. Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and 
mutagenesis. Hum Gene Ther 24(2), 119-131 (2013). 
61. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. A serious adverse event after 
successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 
348(3), 255-256 (2003). 
62. Corrigan-Curay J, Cohen-Haguenauer O, O'reilly M et al. Challenges in vector and 
trial design using retroviral vectors for long-term gene correction in hematopoietic stem 
cell gene therapy. Mol Ther 20(6), 1084-1094 (2012). 
63. Bischof D, Cornetta K. Flexibility in cell targeting by pseudotyping lentiviral 
vectors. Methods Mol Biol 614 53-68 (2010). 
64. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction 
of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996). 
* First demonstration of a lentivirus vector (HIV) to target non-dividing cells both in vitro 
and in an in vivo model. 
65. Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ. Pseudotype-
based neutralization assays for influenza: a systematic analysis. Front Immunol 6 161 
(2015). 
66. Garcia JM, Lai JCC. Production of influenza pseudotyped lentiviral particles and 
their use in influenza research and diagnosis: an update. Expert Review of Anti-Infective 
Therapy 9(4), 443-455 (2011). 
67. Bentley EM, Mather ST, Temperton NJ. The use of pseudotypes to study viruses, 
virus sero-epidemiology and vaccination. Vaccine 33(26), 2955-2962 (2015). 
68. Xiong X, Corti D, Liu J et al. Structures of complexes formed by H5 influenza 
hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proc Natl 
Acad Sci U S A 112(30), 9430-9435 (2015). 
  
25 
 
69. Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-
spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 
16(3), 265-273 (2009). 
70. Suzuki Y, Suzuki Y. Gene Regulatable Lentiviral Vector System.  
doi:16788(2011). 
71. Sandrin V, Cosset FL. Intracellular versus cell surface assembly of retroviral 
pseudotypes is determined by the cellular localization of the viral glycoprotein, its 
capacity to interact with Gag, and the expression of the Nef protein. J Biol Chem 281(1), 
528-542 (2006). 
72. Takeuchi Y, Simpson G, Vile RG, Weiss RA, Collins MK. Retroviral pseudotypes 
produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-
type, retroviruses. Virology 186(2), 792-794 (1992). 
73. Takada A, Robison C, Goto H et al. A system for functional analysis of 
Ebola virus glycoprotein. Proceedings of the National Academy of Sciences 94(26), 
14764-14769 (1997). 
74. Zheng H, Tian H, Jin Y et al. Development of a hamster kidney cell line expressing 
stably T7 RNA polymerase using retroviral gene transfer technology for efficient rescue 
of infectious foot-and-mouth disease virus. J Virol Methods 156(1-2), 129-137 (2009). 
75. Whitt MA. Generation of VSV pseudotypes using recombinant DeltaG-VSV for 
studies on virus entry, identification of entry inhibitors, and immune responses to 
vaccines. J Virol Methods 169(2), 365-374 (2010). 
* Details a very comprehensive protocol for the establishment of the recombinant VSV 
system as a backbone for generating PVs. 
76. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y. Reverse 
genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not 
essential for replication in cell culture. J Virol 76(1), 406-410 (2002). 
77. Ferrara F, Molesti E, Bottcher-Friebertshauser E et al. The human 
Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A 
virus pseudotypes. J Mol Genet Med 7 309-314 (2012). 
  
26 
 
This is the first report in the literature of the production of pseudotypes for 
representative strains of all Group 2 influenza viruses. This represents a significant tool 
for therapeutic screening applications 
78. Dring MM, Morrison MH, Mcsharry BP et al. Innate immune genes synergize to 
predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci 
U S A 108(14), 5736-5741 (2011). 
79. Bottcher E, Matrosovich T, Beyerle M, Klenk HD, Garten W, Matrosovich M. 
Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from 
human airway epithelium. J Virol 80(19), 9896-9898 (2006). 
80. Jardetzky TS, Lamb RA. Activation of paramyxovirus membrane fusion and virus 
entry. Curr Opin Virol 5 24-33 (2014). 
81. Shirato K, Matsuyama S, Ujike M, Taguchi F. Role of proteases in the release of 
porcine epidemic diarrhea virus from infected cells. J Virol 85(15), 7872-7880 (2011). 
82. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike 
protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the 
National Academy of Sciences of the United States of America 106(14), 5871-5876 
(2009). 
83. Kido H, Niwa Y, Beppu Y, Towatari T. Cellular proteases involved in the 
pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza 
virus A and Sendai virus. Adv Enzyme Regul 36 325-347 (1996). 
84. Chaipan C, Kobasa D, Bertram S et al. Proteolytic activation of the 1918 influenza 
virus hemagglutinin. J Virol 83(7), 3200-3211 (2009). 
85. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A 
transmembrane serine protease is linked to the severe acute respiratory syndrome 
coronavirus receptor and activates virus entry. J Virol 85(2), 873-882 (2011). 
86. Simmons G, Rennekamp AJ, Bates P. Proteolysis of SARS-associated coronavirus 
spike glycoprotein. Advances in experimental medicine and biology 581 235-240 (2006). 
  
27 
 
87. Gierer S, Bertram S, Kaup F et al. The spike protein of the emerging 
betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by 
TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87(10), 5502-5511 (2013). 
88. Kawase M, Shirato K, Matsuyama S, Taguchi F. Protease-mediated entry via the 
endosome of human coronavirus 229E. J Virol 83(2), 712-721 (2009). 
89. Robison CS, Whitt MA. The Membrane-Proximal Stem Region of Vesicular 
Stomatitis Virus G Protein Confers Efficient Virus Assembly. Journal of Virology 74(5), 
2239-2246 (2000). 
90. Sandrin V, Muriaux D, Darlix JL, Cosset FL. Intracellular trafficking of Gag and 
Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol 
78(13), 7153-7164 (2004). 
91. Murakami T, Freed EO. The long cytoplasmic tail of gp41 is required in a cell type-
dependent manner for HIV-1 envelope glycoprotein incorporation into virions. 
Proceedings of the National Academy of Sciences of the United States of America 97(1), 
343-348 (2000). 
92. Stitz J, Buchholz CJ, Engelstadter M et al. Lentiviral vectors pseudotyped with 
envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia 
virus 10A1. Virology 273(1), 16-20 (2000). 
93. Buonocore L, Blight KJ, Rice CM, Rose JK. Characterization of vesicular stomatitis 
virus recombinants that express and incorporate high levels of hepatitis C virus 
glycoproteins. J Virol 76(14), 6865-6872 (2002). 
94. Carpentier DC, Vevis K, Trabalza A et al. Enhanced pseudotyping efficiency of 
HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope 
glycoprotein. Gene Ther 19(7), 761-774 (2012). 
** The detailed experiments provided within this manuscript provide crucial information 
regarding which domain(s) of Rhabdovirus VEPs are important for efficient incorporation 
into PVs. It highlights the role the cytoplasmic C domain alone plays in generating high 
titer PVs. 
  
28 
 
95. Bentley EA, R.; Horton, D.; Banyard, A. C.; Wright, E. . Pseudotyped virus-based 
serology studies show Arctic-like rabies viruses are sensitive to existing vaccines and 
biologicals. Society of General Microbiology Annual Conference 2015  (2015). 
96. Kohl W, Zimmer G, Greiser-Wilke I, Haas L, Moennig V, Herrler G. The surface 
glycoprotein E2 of bovine viral diarrhoea virus contains an intracellular localization 
signal. J Gen Virol 85(Pt 5), 1101-1111 (2004). 
97. Lei Y, Joo KI, Zarzar J, Wong C, Wang P. Targeting lentiviral vector to specific cell 
types through surface displayed single chain antibody and fusogenic molecule. Virology 
journal 7 35 (2010). 
98. Frecha C, Costa C, Negre D et al. Stable transduction of quiescent T cells without 
induction of cycle progression by a novel lentiviral vector pseudotyped with measles 
virus glycoproteins. Blood 112(13), 4843-4852 (2008). 
99. Sung VM, Lai MM. Murine retroviral pseudotype virus containing hepatitis B virus 
large and small surface antigens confers specific tropism for primary human 
hepatocytes: a potential liver-specific targeting system. J Virol 76(2), 912-917 (2002). 
100. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral 
vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 9(17), 
1155-1162 (2002). 
101. Lizee G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. Real-time 
quantitative reverse transcriptase-polymerase chain reaction as a method for 
determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther 
14(6), 497-507 (2003). 
102. Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. Factors 
influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther 15(10), 976-988 
(2004). 
103. Vermeire J, Naessens E, Vanderstraeten H et al. Quantification of reverse 
transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, 
lenti- and retroviral vectors. PloS one 7(12), e50859 (2012). 
  
29 
 
104. Heider S, Metzner C. Quantitative real-time single particle analysis of virions. 
Virology 462-463 199-206 (2014). 
105. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis 
virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and 
efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S 
A 90(17), 8033-8037 (1993). 
106. Cepko C. Large-Scale Preparation and Concentration of Retrovirus Stocks. In: 
Current Protocols in Molecular Biology, (Ed.^(Eds).John Wiley & Sons, Inc.  (2001). 
107. Aboud M, Wolfson M, Hassan Y, Huleihel M. Rapid purification of extracellular and 
intracellular Moloney murine leukemia virus. Arch Virol 71(3), 185-195 (1982). 
108. Burgess-Brown NA, Sharma S, Sobott F, Loenarz C, Oppermann U, Gileadi O. 
Codon optimization can improve expression of human genes in Escherichia coli: A multi-
gene study. Protein Expression and Purification 59(1), 94-102 (2008). 
109. Lanza AM, Curran KA, Rey LG, Alper HS. A condition-specific codon optimization 
approach for improved heterologous gene expression in Saccharomyces cerevisiae. BMC 
Syst Biol 8 33 (2014). 
110. Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. Viruses 
6(7), 2531-2550 (2014). 
111. Jenkins GM, Holmes EC. The extent of codon usage bias in human RNA viruses 
and its evolutionary origin. Virus Res 92(1), 1-7 (2003). 
112. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. 
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-
CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 101(12), 4240-
4245 (2004). 
113. Jounai N, Okuda K, Kojima Y et al. Contribution of the rev gene to the 
immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 
5(7), 609-617 (2003). 
114. Mckeating JA, Zhang LQ, Logvinoff C et al. Diverse hepatitis C virus glycoproteins 
mediate viral infection in a CD81-dependent manner. J Virol 78(16), 8496-8505 (2004). 
  
30 
 
115. Bartosch B, Cosset FL. Studying HCV cell entry with HCV pseudoparticles 
(HCVpp). Methods Mol Biol 510 279-293 (2009). 
116. Doty RT, Sabo KM, Chen J, Miller AD, Abkowitz JL. An all-feline retroviral 
packaging system for transduction of human cells. Hum Gene Ther 21(8), 1019-1027 
(2010). 
117. Miller AD, Garcia JV, Von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction 
and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 
65(5), 2220-2224 (1991). 
118. Sanber KS, Knight SB, Stephen SL et al. Construction of stable packaging cell 
lines for clinical lentiviral vector production. Sci Rep 5 9021 (2015). 
119. Vogt B, Roscher S, Abel B et al. Lack of superinfection interference in retroviral 
vector producer cells. Hum Gene Ther 12(4), 359-365 (2001). 
120. Tarr AW, Owsianka AM, Szwejk A, Ball JK, Patel AH. Cloning, expression, and 
functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol 
379 177-197 (2007). 
121. Giang E, Dorner M, Prentoe JC et al. Human broadly neutralizing antibodies to the 
envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109(16), 
6205-6210 (2012). 
122. Yang YW, Yang JC. Effect of polyionic compounds on the adsorption of polyoma 
virus. Antiviral Res 33(1), 33-39 (1996). 
123. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate 
retrovirus transduction via membrane charge neutralization and virus aggregation. 
Biophys J 86(2), 1234-1242 (2004). 
 
 
  
  
31 
 
Highlighted References 
1. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing 
functional E1-E2 envelope protein complexes. J Exp Med 197(5), 633-642 (2003). This 
paper was the first description of a tractable experimental system for interrogating the 
hepatitis C virus entry pathway and the effect of genetic diversity on entry fitness. It also 
facilitated assessment of the potency of HCV-neutralising antibodies. 
2. Ferrara F, Molesti E, Bottcher-Friebertshauser E et al. The human Transmembrane 
Protease Serine 2 is necessary for the production of Group 2 influenza A virus 
pseudotypes. J Mol Genet Med 7 309-314 (2012). This is the first report in the literature of 
the production of pseudotypes for representative strains of all Group 2 influenza viruses. 
This represents a significant tool for therapeutic screening applications. 
3. Whitt MA. Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on 
virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol 
Methods 169(2), 365-374 (2010). Details a very comprehensive protocol for the 
establishment of the recombinant VSV system as a backbone for generating PVs.  
  
  
32 
 
Figure legends 
Figure 1. Schematic of the basic three-plasmid approach to generation of a pseudotyped 
virus with a retroviral core. 
 
Figure 2. Summary diagram of factors to consider when generating a pseudotyped virus 
expressing a novel viral envelope protein. 
 
Figure 3. Schematic of generation of a pseudotyped virus with a vesicular stomatitis 
virus (VSV) core.  
  
33 
 
 
 
 
  
  
34 
  
  
35 
 
 
